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Janssen-Cilag, Neuss, NRW, Germany, 2 Janssen-Cilag GmbH, Neuss, NRW, Germany OBJECTIVES: Elderly patients with impaired renal function or with a risk of kidney failure due to diabetes mellitus (DM) or with hypertension are at risk for accumulation of metabolites from certain opioids as well as for drug-drug interactions (DDI) because of their multimorbidity. The purpose of this analysis is to analyze the share of patients treated with opioids prone to accumulation of metabolites (e.g. morphine) or DDI via CYP450 (e.g. oxycodone, tramadole) in Germany. METHODS: This study was performed using retrospective longitudinal aggregated patient data from the IMS Disease Analyzer. All patients 65 years or older with at least one diagnosis of DM (ICD10 E10-E14), hypertension (I10-I15), renal failure (N17-N19), glomerular disease (N00-N08) or renal tubulo-interstitial disease (N10-N16) with at least two prescriptions of extended-release (ER) morphine, hydromorphone, oxycodone or tramadole in 2008 were included. The "P450 Drug Interaction Table" of the Indiana University was used as the source for substances with potential DDI. RESULTS: A total of 6565 patients aged 65 years or more with at least two ER opioids prescriptions in 2008 met the criteria of the high risk group for DDI and metabolite accumulation because of impaired renal function/ risk of kidney failure. A total of 702 (10.7%) patients from this group were treated with morphine, 528 (8.0)% with hydromorphone, 1.603 (24.4%) with oxycodone, 3.732 (56.8%) with tramadole. Fifty-two percent of patients treated with oxycodone and 44% of those treated with tramadole concomitantly received a systemic therapy with a potential risk of DDI. CONCLUSIONS: The majority of patients were treated with an opioid prone to accumulation of metabolites or DDI that can cause additional costs. For this group of patients the choice of hydromorphone can possibly avoid these potential complications.
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PCV1 MISDIAGNOSIS AND MISTREATMENT OF A COMMON SIDE-EFFECT-ACE INHIBITOR INDUCED COUGH
Vegter S, Boersma C, De Jong-van den Berg LTW University of Groningen, Groningen, The Netherlands OBJECTIVES: Angiotensin converting enzyme inhibitors (ACEi) are frequently presAngiotensin converting enzyme inhibitors (ACEi) are frequently prescribed for various cardiac and renal diseases. A common side-effect of these drugs is a persistent dry cough. Physicians who fail to recognise a dry cough to be ACEi related may attemp to treat it with antitussive agents, in stead of recommended ACEi substitution. Prescription behaviour in the general population considering treatment of the side-effect with antitussive agents has not been studied before. METHODS: Drug Drug dispensing data between 2000 and 2007 were retrieved from the IADB.nl database.
IADB.nl database. A prescription sequence symmetry analysis was used to determine whether antitussive prescription sequence symmetry analysis was used to determine whether antitussive agents were prescibed more often following ACEi initiation than the other way around. A logistic regression model was fitted to determine predictors.
ogistic regression model was fitted to determine predictors. RESULTS: A total of 1054 patients were incident users of both ACEi and antitussives within a 1054 patients were incident users of both ACEi and antitussives within a half-year time span. There was an excess of patients being prescibed antitussive agents after ACEi initiation, adjusted Sequence Ratio 2.2 (CI: 1.9-2.4). Females were more likely to be prescribed antitussive agents following ACEi therapy initiation, Odds Ratio 1.4 (CI: 1.1-1.9), age and comedications were no significant predictors. CON-CLUSIONS: There was a significant and clinically relevant excess of patients receiving
There was a significant and clinically relevant excess of patients receiving antitussives after ACEi initiation. The results suggest that cough as a side-effect of ACEi is not recognized as being ACEi related or is symptomatically treated with antitussive agents in stead of ACEi substitution. The estimated frequency of antitussive treatment of ACEi induced dry cough is 15%. Further results will be presented on cost implications of unnecassary drug use and decreased ACEi therapy compliance.
PCV2 INCREASED RISK OF MORTALITY AND CO-MORBIDITIES IN PATIENTS WITH UNTREATED PRIMARY HYPERPARATHYROIDISM
Yu N, Leese GP, Donnan PT University of Dundee, Dundee, UK OBJECTIVES: Primary hyperparathyroidism (PHPT) is the third most common endocrine disorder, with the majority changed being asymptomatic. Parathyroidectomy (PTX), as the only definite treatment, is available to severe PHPT (~20%). We evaluated the mortality and co-morbidities in patients with PHPT with aim to estimate long-term impact of those untreated patients on the health care system. METHODS: This is a retrospective population-based cohort study. Using a unique patient identifier in Tayside, Scotland, electronic record-linkage enabled a dataset of PHPT patients to be created from an algorithm of biochemistry and nuclear scan records, hospital admission data and community based prescriptions. Three additional datasets were added in order to measure the mortality and co-morbidities in comparison with the general population using standardised mortality/morbidity ratios (SMRs) and standardised incidence ratios (SIRs). Patients were split into 'mild' and 'aggressive' groups broadly following the NIH criteria for PTX. RESULTS: During the decade of 1997 to 2006, we identified 2299 patients (70.4% female), 1683 (73.2%) as having mild PHPT. A third of the aggressive PHPT patients (32.8%) had undergone PTX. We found an increased risk of all-cause mortality (SMR: 2.58, 95% CI (2.39-2.79)) as well as cardiovascular and cancer related deaths (SMR: 2.49 (2.21-2.80); 3.02 (2.60-3.48) respectively) in all patients. The risk is similar between the mild and the unoperated aggressive groups, but slightly reduced in the operated group. Unoperated patients (both mild and aggressive) were also associated with high risk of comorbidities, with renal disease being the highest. Surgery significantly improved patients' health outcomes. CONCLUSIONS: The population prevalence of PHPT has generally increased; incidence is greater in females and increases with age. Mortality and morbidity are similarly higher for patients with mild and unoperated aggressive PHPT. Surgery may be worth recommending to all patients, and further study of the cost-effectiveness of surgery and chemotherapy is planned.
PCV3 USE OF SPIRONOLACTONE IN THE TREATMENT OF CONGESTIVE HEARTH FAILURE
Lachaine J 1 , Beauchemin C 2 , Ramos É 3 1 University of Montreal, Montréal, QC, Canada, 2 University of Montreal, Montreal, QC, Canada, 3 Pfizer Canada Inc, Kirkland, QC, Canada OBJECTIVES: Aldosterone plays an important role in the pathophysiology of congestive heart failure (CHF). Blockade of aldosterone receptors by spironolactone substantially reduces risk of morbidity and mortality among patients with CHF. However, benefits of spironolactone are potentially limited by its treatment compliance and adverse events profile, particularly hyperkalemia and gynecomastia. The purpose of this study was to estimate the use of spironolactone in patients with CHF, the incidence of key adverse events and patients compliance to spironolactone. METHODS: This study was performed using data from the Quebec provincial medical and drug plans (RAMQ). Data on medical and pharmaceutical services from January 2000 to September 2008 were obtained from the RAMQ for patients who had a diagnosis of CHF (ICD-9 codes 4280-4289) during that period. Relative incidence of gynecomastia and hyperkalemia was estimated for users and non users of spironolactone. Treatment adherence was estimated for initial users of spironolactone and compared
